BioLineRx (BLRX) Q2 2026 earnings review
GLIX1 Pipeline Expands as Legacy Royalty Stream Stumbles
BioLineRx is advancing its pivot to early-stage oncology, but the financial foundation is showing cracks. The lead asset, GLIX1, continues to generate promising preclinical data, prompting management to add an ovarian cancer arm to the upcoming Phase 2a trial. However, the non-dilutive royalty stream from partner Ayrmid (APHEXDA) unexpectedly reversed, with partner sales dropping 36% sequentially to $1.6 million. With cash dwindling to just $13.1 million, the company was forced into a highly dilutive $3.75 million direct offering immediately after the quarter closed to preserve its 'H1 2027' runway guidance.
🐂 Bull Case
New in vivo data demonstrating strong synergy between GLIX1 and PARP inhibitors in HR-proficient ovarian cancer provides a clear, scientifically validated expansion pathway beyond the initial Glioblastoma (GBM) indication.
The Phase 2b CheMo4METPANC trial for motixafortide remains on track for a prespecified interim futility analysis in 2026, offering a potential binary upside event if the efficacy signal remains strong.
🐻 Bear Case
After sequential growth in previous quarters, Ayrmid's commercial sales of APHEXDA abruptly decelerated from $2.5M in Q1 to $1.6M in Q2. If this trend continues, BioLineRx's primary non-dilutive funding source is compromised.
With only $13.1M in cash at quarter-end and R&D burn accelerating to $2.9M, the company is operating with almost zero margin for error. The post-quarter $3.75M micro-raise highlights the urgent need for constant capital influx.
⚖️ Verdict: 🔴
Bearish. The clinical progress of GLIX1 is encouraging, but biotech is a race between data and cash. The sudden drop in APHEXDA sales removes a critical financial safety net, forcing the company to dilute shareholders at depressed valuations just to keep the lights on through upcoming clinical milestones.
Key Themes
GLIX1 Pipeline Expansion via Synthetic Lethality
Management announced new in vivo data showing a strong synergistic effect between GLIX1 and PARP inhibitors in HR-proficient ovarian cancer models. Notably, the low-dose GLIX1/olaparib combination achieved tumor reduction comparable to cisplatin. This scientifically validates GLIX1's mechanism of targeting the DNA damage response (DDR) and has prompted the addition of an ovarian cancer arm to the Phase 2a expansion trial. Discussions with PARP inhibitor companies for development collaborations are now underway.
APHEXDA Commercial Momentum Reversing
After steadily building momentum post-transition, APHEXDA sales by partner Ayrmid experienced a sudden shock. Gross sales dropped from $2.5M in 26Q1 to $1.6M in 26Q2, effectively returning to levels seen a year ago (25Q2: $1.7M). Because BioLineRx has zero control over Ayrmid's commercial execution, this deceleration is a major blind spot and severely threatens the narrative that APHEXDA royalties will fund the GLIX1 clinical program.
Accelerating Burn vs. Dwindling Cash
R&D expenses are accelerating exactly as expected to support the GLIX1 trial, rising from $2.3M in 25Q2 to $2.5M in 26Q1, and now $2.9M in 26Q2. Meanwhile, cash balances have decayed sequentially for over a year, hitting $13.1M. Management claims this funds operations into H1 2027, but the execution of a $3.75M direct offering immediately after the quarter closed suggests internal models showed a dangerously tight runway.
Motixafortide mPDAC Trial Nears Binary Catalyst
Enrollment continues in the CheMo4METPANC Phase 2b trial led by Columbia University. Management confirmed the prespecified interim/futility analysis is still anticipated to occur in 2026 once 40% of progression-free survival (PFS) events are observed. This remains the most significant near-term catalyst for the legacy pipeline, though the shifting competitive landscape in PDAC continues to loom over the program's ultimate commercial viability.
Other KPIs
Accelerating. Up 26.5% YoY from $2.3M in 25Q2 and up sequentially from $2.5M in 26Q1. This line item will continue to climb as the GLIX1 Phase 1/2a trial advances through its 5 planned cohorts and prepares for the Phase 2a expansion phase.
Artificially inflated YoY growth. The 313.9% jump from $0.2M in 25Q2 is heavily skewed by a one-time $0.8M reversal of a provision for doubtful accounts (from Gloria Biosciences) that artificially lowered the baseline in the prior-year period. True G&A run-rate remains relatively stable.
Guidance
Stable. The company is maintaining its guidance that current capital will last into the first half of 2027. However, achieving this target clearly required the post-quarter $3.75M capital raise, indicating the organic cash flow from royalties is insufficient to cover the escalating GLIX1 trial costs.
Stable. The dose escalation phase is progressing predictably, having commenced Cohort 2 in July and targeting Cohort 3 in September. This predictable pacing suggests no early dose-limiting toxicities have derailed the timeline.
Stable. The trial remains on schedule to hit its 40% PFS event threshold before the end of the year, setting up a critical data readout.
Key Questions
APHEXDA Commercial Deceleration
Partner sales of APHEXDA dropped roughly 36% sequentially from Q1 to Q2. Given you have no direct control over the sales force, what insights has Ayrmid provided regarding this abrupt slowdown in adoption?
Cost of the Ovarian Cancer Arm
You've announced plans to add an ovarian cancer arm to the Phase 2a expansion of GLIX1. Is the cost of this additional cohort fully factored into your current 'H1 2027' cash runway guidance, or does this require the establishment of a development collaboration first?
PARP Inhibitor Collaboration Structure
Regarding your ongoing discussions with PARP inhibitor companies, are you primarily seeking clinical supply agreements for the Phase 2a trial, or are you pursuing broader financial/development partnerships to offset clinical costs?